The global congenital hyperinsulinism treatment market size was valued at USD 151.57 million in 2025 and is projected to grow from USD 162.10 million in 2026 to USD 277.49 million by 2034, registering a CAGR of 6.95 % during the forecast period (2026-2034). North America dominated the congenital hyperinsulinism treatment market with a share of 40.87% in 2025.
Congenital hyperinsulinism treatment involves medical and surgical approaches used to manage a rare genetic condition in which pancreatic beta cells release excessive insulin, causing dangerously low blood glucose levels. Congenital hyperinsulinism treatments are commonly classified under HSN Code 3004 (medicaments for therapeutic or prophylactic uses, put up in measured doses or retail packaging) and SIC Code 2834 (Pharmaceutical Preparations).
The congenital hyperinsulinism treatment market demand is driven by the need for reliable blood glucose control and the importance of preventing hyperinsulinemic hypoglycemia-related complications in infants and children. Healthcare providers are increasingly using diazoxide, somatostatin analogs, glucagon therapy, and specialized surgical interventions, contributing to congenital hyperinsulinism treatment market growth.
Download a Free Sample To learn more about this report,
Shift toward Targeted Drug Therapies for Congenital Hyperinsulinism
The congenital hyperinsulinism treatment market analysis shows a shift toward targeted drug therapies that help control excessive insulin secretion and maintain stable blood glucose levels. These treatments aim to address specific disease mechanisms and improve glucose control in affected children.
Development of Novel Therapies for Diazoxide Unresponsive Patients
Research into the congenital hyperinsulinism treatment market is increasingly focused on novel therapies for patients who do not respond adequately to diazoxide, the standard first-line medication. Researchers are exploring alternative drugs that target insulin secretion pathways and help prevent severe hypoglycemia.
Supply chain disruptions are expected to have a high impact on the congenital hyperinsulinism treatment market share due to dependence on specialized medicines, active pharmaceutical ingredients, and pharmaceutical distribution networks. The market is expected to follow a stair-step recovery, as disruptions in pharmaceutical distribution can affect treatment availability in phases before supplies and production capacity stabilize. The market is expected to grow at a CAGR of 6.95%, but supply chain constraints could lower this by 0.9 percentage points, resulting in a growth of around 6.05%. As supply conditions normalize, the congenital hyperinsulinism treatment market growth is expected to gradually return to 6.95%.
The congenital hyperinsulinism treatment market forecasts strategic investment activity driven by research into insulin-receptor antagonists, the development of targeted therapeutic candidates, and the advancement of novel treatment approaches. In August 2026, Stanford University received USD 676,000 in federal research funding to investigate insulin-receptor antagonism and develop potential therapeutic candidates for congenital hyperinsulinism.
Demand for Effective Hypoglycemia Control and Expansion of Specialized Pediatric Endocrinology Services Drives Market
Demand for effective hypoglycemia control is growing as congenital hyperinsulinism causes excessive insulin production, resulting in dangerously low blood glucose levels. Treatment aims to maintain stable glucose levels and reduce the risk of severe complications, including neurological damage. This creates a need for effective medicines and continuous glucose monitoring to support timely treatment adjustments.
Expansion of specialized pediatric endocrinology services is supporting demand for congenital hyperinsulinism treatments as more children require expert care for disorders affecting insulin production and blood glucose regulation. Specialized centers provide access to diagnostic evaluation, medication management, nutritional support, and ongoing glucose monitoring. These services help healthcare providers develop treatment plans based on disease severity and individual patient needs.
Risk of Adverse Effects from Existing Therapies and Need for Continuous Patient Monitoring Restraints Market Expansion
Risk of adverse effects from existing therapies can create challenges in congenital hyperinsulinism treatment. Medications used to control excessive insulin secretion may cause side effects that require dose adjustments or alternative treatment approaches. These risks can complicate long-term disease management and increase the need for medical supervision, potentially limiting treatment options for some patients.
Need for continuous patient monitoring can increase the complexity and cost of congenital hyperinsulinism treatment. Patients, particularly infants and young children, require frequent blood glucose checks to detect and prevent episodes of dangerously low blood sugar. This can place a burden on caregivers and healthcare providers and may require specialized monitoring equipment and regular clinical support.
Expansion of Genetic Testing and Specialized Care Programs Offers Growth Opportunities
Diagnostic laboratories, genetic testing providers, and pediatric hospitals can target families and healthcare professionals seeking to identify the genetic causes of congenital hyperinsulinism. Genetic testing can help classify the condition, support treatment decisions, and identify eligible patients for targeted therapeutic approaches. Revenue can be generated through genetic testing services, specialized diagnostic packages, laboratory partnerships, and hospital service agreements, contributing to congenital hyperinsulinism treatment market growth.
Children’s hospitals, pediatric endocrinology centers, and specialized care providers can develop dedicated programs for children requiring long-term management of congenital hyperinsulinism. These programs can combine treatment planning, nutritional guidance, glucose monitoring, and follow up consultations to support coordinated care.
Medication held the leading position in the treatment type segment in 2025, capturing a 61.84% share, supported by its established role in controlling excessive insulin secretion and maintaining stable blood glucose levels.
The dietary management segment is projected to register a CAGR of 6.76% during the forecast period, driven by the need for individualized feeding plans, frequent meals, and nutritional strategies to prevent hypoglycemia.
Request Customizationto receive a tailored report.
Diffuse congenital hyperinsulinism (CHI) accounted for a 59.28% share of the disease type segment in 2025, reflecting the involvement of insulin-producing cells throughout the pancreas. Treatment often involves medication, carefully planned feeding schedules, and regular blood glucose monitoring to prevent recurrent hypoglycemia.
The focal CHI segment is projected to register a CAGR of 6.74% during the forecast period, supported by advances in disease localization and targeted surgical approaches for patients with localized pancreatic lesions.
Hospitals dominated the end user segment in 2025, representing 68.35% of the market, owing to their specialized pediatric care facilities, continuous glucose monitoring capabilities, and capacity to manage severe hypoglycemia and complex treatment needs.
The homecare settings segment is expected to achieve a CAGR of 7.54% during the forecast period, driven by increasing emphasis on long term disease management, home glucose monitoring, and caregiver led treatment routines that help reduce frequent hospital visits.
Speak to an Analystto discuss market opportunities.
The North America congenital hyperinsulinism treatment market accounted for a share of 40.87% in 2025.
U.S. market is shaped by clinical research at the Children’s Hospital of Philadelphia (CHOP) evaluating continuous intravenous glucagon for infants with severe congenital hyperinsulinism. A clinical study reported that glucagon infusion reduced glucose infusion requirements and the frequency of hypoglycemic episodes, highlighting the role of glucagon therapy in stabilizing blood glucose when conventional treatment is insufficient.
Canada supports specialized pediatric endocrinology services at The Hospital for Sick Children (SickKids) in Toronto, which provides diagnosis and ongoing management for children with congenital hyperinsulinism. Its specialized care includes blood glucose monitoring, nutritional management, and medication-based treatment to control excessive insulin secretion and prevent recurrent hypoglycemia.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific congenital hyperinsulinism treatment market is projected to grow at a CAGR of 9.46% during the forecast period, making it the fastest-growing region.
China’s multicenter study involving 122 children treated at two major Chinese pediatric centers reported a 93% success rate with octreotide therapy alone. These findings highlight progress in managing pediatric hypoglycemia and insulin secretion disorders, particularly among children who do not respond adequately to diazoxide.
Japanese Society for Pediatric Endocrinology and the Japanese Society of Pediatric Surgeons developed clinical practice guidelines. These guidelines outline medical treatment, diagnostic approaches, and criteria for partial or near-total pancreatectomy when hypoglycemia cannot be adequately controlled. This supports evidence-based management of insulin secretion disorders and the use of pancreatic surgery in appropriately selected children.
Specialized pediatric endocrine care at the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh provides diagnostic and treatment services for children with complex endocrine disorders. These services support the identification and management of congenital hyperinsulinism through blood glucose monitoring, medication-based treatment, and specialist evaluation of children with persistent hypoglycemia.
Europe's congenital hyperinsulinism treatment market will expand to grow at 6.72% CAGR during the forecast period.
UK Government’s Rare Diseases Framework, supported by the England Rare Diseases Action Plan 2026, prioritizes faster diagnosis, better coordination of care, and improved access to specialist treatments. These initiatives create opportunities for providers of pediatric endocrinology services, glucose monitoring technologies, and congenital hyperinsulinism treatments, including therapies and surgical interventions for children whose hypoglycemia cannot be adequately controlled through standard medical management.
National Action League for People with Rare Diseases (NAMSE) promotes coordinated diagnostic pathways, specialist treatment centers, and collaboration among healthcare providers. These efforts create opportunities for pediatric endocrinology services, glucose monitoring technologies, and congenital hyperinsulinism treatments, supporting earlier identification of persistent hypoglycemia and coordinated management of children with rare insulin secretion disorders.
The Latin America congenital hyperinsulinism treatment market is likely to grow at a CAGR of 6.38% during the forecast period. Brazil’s National Neonatal Screening Program (PNTN) provides a framework for early detection, diagnosis, follow-up, and treatment of selected congenital conditions, including congenital hypothyroidism and congenital adrenal hyperplasia.
Mexico’s National Neonatal Screening Program promotes early detection of congenital and metabolic diseases in newborns. The program’s diagnostic framework and referral pathways support timely evaluation of infants with suspected metabolic abnormalities.
The Middle East & Africa congenital hyperinsulinism treatment market is anticipated to register a CAGR of 6.11% during the forecast period. UAE's National Newborn Screening Guidelines, introduced by the Ministry of Health and Prevention, standardize early detection, diagnosis, and referral for genetic, metabolic, and endocrine disorders. Abu Dhabi’s Newborn Genetic Screening Program further expands early identification of actionable childhood genetic conditions.
A documented case presented at the South African Society of Nuclear Medicine Congress described a late presenting congenital hyperinsulinemia diagnosed at Universitas Academic Hospital in Bloemfontein using 18F-DOPA PET imaging. This case highlights the role of advanced pancreatic imaging in identifying the underlying disease pattern.
The congenital hyperinsulinism treatment market competitive landscape is highly fragmented, with established pharmaceutical companies, rare disease drug developers, and specialized biotechnology firms. Key players such as Teva Pharmaceuticals, Xeris Biopharma, Novartis, Zealand Pharma, and Crinetics Pharmaceuticals are estimated to account for 25–30% of the global congenital hyperinsulinism treatment market share.
Established players compete mainly through clinical research, focus on treatment safety, and regulatory approvals for rare endocrine disorders. Emerging and regional players in the congenital hyperinsulinism treatment market ecosystem focus on targeted therapies and specialized solutions for patients who do not respond adequately to existing treatments.
September 2026: Rezolute continued its Phase III upLIFT trial of ersodetug for tumor-related hyperinsulinism, supporting the development of treatment options for persistent hypoglycemia.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Acute Kidney Injury Treatment Market Size, Forecast, Demand, 2034
Clinical Trial Packaging Market Size, Forecast, Demand, 2034
Ibuprofen Market Size, Share, Growth, Analysis, Report, 2034
Cryptococcosis Market Size, Forecast, Demand, Opportunities, 2034
Apixaban Market Size, Forecast, Demand, Opportunities, 2034
Asbestosis Treatment Market Size, Forecast, Demand, 2034
We are featured on:
sales@straitsresearch.com